Amarin Corp Plc (AMRN)

[north40000]

Some of us will remember the essentially “free advertising” Amarin obtained when the top-line and final data results from Reduce-It clinical trial were released in 2019-2020. Long stories with video interviews of Amarin’s CEO, Dr. Bhatt and various other knowledgeable cardiologists and endocrinologists were featured in the Washington Post, New York Times, Wall Street Journal and Bloomberg(Vascepa “works”, said JT), among many others. Prospective patients and prescribing doctors read those stories.

I am confident that Amarin management and BOD, and Sarissa/Dr. Denner will find a timely way to make those publications aware of Vascepa’s new CVD risk reduction and other disease treatment data that Amarin has accumulated since, particularly the data released this past week at the ACC scientific session—why and how Vascepa “works.”